Correction to: BMC Cancer 21, 904 (2021)

https://doi.org/10.1186/s12885-021-08630-w

Following publication of the original article [1], it was noticed that uncorrected page proofs were mistakenly published. The publishers apologise for this error. The original article [1] has been corrected.

Below is a table of corrections which have been implemented in the original article.

Section

Originally published text

Corrected text

Article note

Rajesh Kaldate7 & Evelyn Wang7

Rajesh Kaldate7† & Evelyn Wang7†

†Affiliation at the time of the study.

Abstract

Trial registration: ClinicalTrials.gov NCT01865747 (registered on 05/31/2013).

Trial registration: ClinicalTrials.gov NCT01865747 (registered on 05/31/2013). https://clinicaltrials.gov/ct2/show/NCT01865747

Table 1 note

Plasma biomarker baseline and fold change data were available for 316 and 304 patients in the cabozantinib arm and 305 and 280 patients in the everolimus

arm, respectively, with the exception of for IL-8 in the everolimus arm, for which 304 and 279 patients had available data, respectively

Plasma biomarker baseline and fold change data were available for 316 and 304 patients in the cabozantinib arm and 305 and 280 patients in the everolimus arm, respectively, with the exception of IL-8 in the everolimus arm, for which 304 and 279 patients had available data, respectively

Figure 1

Footnote is missing

High levels and low levels are defined by ≥median and < median, respectively.

NR, not reached.

Row 2

1.32 (0.95–1.83)

1.32 (0.95, 1.83)

Row 6

ΔIL8

ΔIL-8

Table 6

Row 11

IL8

IL-8

Table 6

Row 12

0.97 (0.87–1.07)

0.97 (0.87, 1.07)

Table 6

Row 16

ΔIL8

ΔIL-8

Table 6

Row 18

IL8

IL-8

Table 6

Row 21

IL8 / 1.35 (0.95–1.9)

IL-8 / 1.35 (0.95, 1.9)

Table 6 note

Biomarkers were included in the multivariable analysis if p < 0.10 in the univariate analyses. Hazard ratios are for high versus low biomarker levels. Δ Indicates the covariate is change in the biomarker at week 4; all other covariates are baseline biomarkers dichotomized at the median * p < 0.05 for the analysis

Biomarkers were included in the multivariable analysis if p < 0.10 in the univariate analyses. Hazard ratios are for high versus low biomarker levels.

Δ indicates the covariate is change in the biomarker at week 4; all other covariates are baseline biomarkers dichotomized at the median * p < 0.05 for the analysis

Competing interests

Dr. Powles has received honoraria from Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; has a consulting or advisory role with Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; has received research funding from Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and has received travel/accommodation/other expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche.

Dr. Powles has received honoraria from Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; has a consulting or advisory role with Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; has received research funding from Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, MSD, Novartis, Pfizer, Roche, and Seattle Genetics; and has received travel/accommodation/other expenses from AstraZeneca, Ipsen, MSD, Pfizer, and Roche.

Competing interests

Dr. Wang is employed by Exelixis; and has stock/ownership interests with Exelixis.

Dr. Wang is a former employee of Exelixis; has stock/ownership interests with Exelixis.

Additional file 1

‘Track changed’ version was published

Clean version is published this correction article and the original article has been udpated